Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

BofA lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $88 and keeps a Buy rating on the shares after the company announced Q3 results that fell short of expectations and lowered ...

Integra LifeSciences Holdings (IART) has an average rating of hold and mean price target of $19.56, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic ...

) has been revised to $100.65 / share. This is an increase of 19.01% from the prior estimate of $84.57 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...

Kodiak Sciences Inc. (NASDAQ: KOD) announced the pricing of an upsized public offering of 6,956,522 shares of common stock at $23.00 per share. The biotechnology company expects gross proceeds of ...

Gilead Sciences (GILD) has an average rating of overweight and mean price target of $160.52, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from ...

Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public offering at $21.00 ...

The average one-year price target for Exact Sciences (NasdaqCM:EXAS) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The ...

Integral Ad Science Holding Corp. IAS will release its financial results for the fourth quarter, before the opening bell, on Friday, Feb. 28, 2025. Analysts expect the New York-based company to report ...

Kodiak Sciences (KOD) has priced an expanded public offering of approximately 6.96 million shares at $23.00 each. The company expects to raise roughly $160 million in gross proceeds. Kodiak Sciences ...